DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian and endometrial cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)

Trial Details

NCT ID
NCT06964009
Phase
PHASE1
Sponsor
Elizabeth Stover, MD, PhD
Status
RECRUITING
Cancer Type
Endometrial Cancer Uterine Cancer
Interventions
  • DT2216
  • Paclitaxel
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Participants must have histologically confirmed relapsed or refractory ovarian cancer (including epithelial ovarian cancer, fallopian tube carcinom…
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diamet…
  • Participants must have received at least one prior platinum-based chemotherapeutic regimen for primary management of disease.
  • Participants must have been treated with at least one line of standard-of-care platinum-based chemotherapy. Otherwise, there is no limit on lines o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Endometrial Cancer Uterine Cancer Trials on Trialify →